Literature DB >> 10522730

Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor.

P A Clavien, M Selzner, M A Morse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10522730      PMCID： PMC1420909          DOI： 10.1097/00000658-199910000-00016

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  17 in total

1.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

Authors:  W D Ensminger; A Rosowsky; V Raso; D C Levin; M Glode; S Come; G Steele; E Frei
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Indicators of prognosis after hepatic resection for colorectal secondaries.

Authors:  J Scheele; R Stangl; A Altendorf-Hofmann; F P Gall
Journal:  Surgery       Date:  1991-07       Impact factor: 3.982

3.  Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

Authors:  M Lorenz; H H Müller; H Schramm; H J Gassel; H G Rau; K Ridwelski; J Hauss; R Stieger; K W Jauch; W O Bechstein; A Encke
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

4.  A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.

Authors:  D C Hohn; R J Stagg; M A Friedman; J F Hannigan; A Rayner; R J Ignoffo; P Acord; B J Lewis
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

5.  Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.

Authors:  J K Martin; M J O'Connell; H S Wieand; R J Fitzgibbons; J A Mailliard; J Rubin; D M Nagorney; L K Tschetter; J E Krook
Journal:  Arch Surg       Date:  1990-08

6.  A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver.

Authors:  L D Wagman; M M Kemeny; L Leong; J J Terz; L R Hill; J D Beatty; W A Kokal; D U Riihimaki
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

7.  Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.

Authors:  P Schlag; M Manasterski; T Gerneth; P Hohenberger; M Dueck; C Herfarth; W Liebrich; V Schirrmacher
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice.

Authors:  J A Houghton; P J Houghton
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

9.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

Authors:  N Kemeny; J Daly; B Reichman; N Geller; J Botet; P Oderman
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

10.  Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial.

Authors:  P Rougier; A Laplanche; M Huguier; J M Hay; J M Ollivier; J Escat; R Salmon; M Julien; J C Roullet Audy; D Gallot
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.